The primary objective of the perioperative study is to evaluate pathological complete response in resectable II-IIIB(N2) KRAS-mutated nonsquamous non-small cell lung cancer participants receiving tislelizumab plus platinum-based doublet chemotherapy.
Able to provide written informed consent (ICF) and able to understand and comply with the study requirements and assessment schedule.
Male or female aged ≥18 years at the time of signing the ICF.
Histologically or cytologically confirmed stage II-IIIB (N2) non-squamous non-small cell lung cancer (NSCLC) (AJCC 8th edition).
With Known KRAS gene mutation.
Previously received any treatment for the current lung cancer, including radiotherapy and all systemic anti-tumor treatments, including chemotherapy, immunotherapy, targeted therapy, or anti-angiogenic therapy.
Presence of locally advanced, unresectable disease, regardless of disease stage or presence of metastases.
Received other approved systemic immunomodulatory agents (including but not limited to interferon, interleukin-2, tumor necrosis factor, thymosin α1, and thymalfasin) within 4 weeks prior to the first dose.
Used any herbal medicine to control cancer within 14 days prior to the first dose of the study drug.